MXPA03009908A - Granulos cubiertos a base de inhibidor de la enzima de conversion de la angiotensina. - Google Patents

Granulos cubiertos a base de inhibidor de la enzima de conversion de la angiotensina.

Info

Publication number
MXPA03009908A
MXPA03009908A MXPA03009908A MXPA03009908A MXPA03009908A MX PA03009908 A MXPA03009908 A MX PA03009908A MX PA03009908 A MXPA03009908 A MX PA03009908A MX PA03009908 A MXPA03009908 A MX PA03009908A MX PA03009908 A MXPA03009908 A MX PA03009908A
Authority
MX
Mexico
Prior art keywords
group
converting enzyme
enzyme inhibitor
angiotensin
granules based
Prior art date
Application number
MXPA03009908A
Other languages
English (en)
Inventor
Chenevier Philippe
Original Assignee
Ethypharm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethypharm Sa filed Critical Ethypharm Sa
Publication of MXPA03009908A publication Critical patent/MXPA03009908A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)

Abstract

La presente invencion se refiere a granulos a base de inhibidor de la enzima de conversion de la angiotensina, sus isomeros o sus sales farmaceuticamente aceptables (IEC) caracterizados por que se cubre y contienen: microcristales de IEC, uno o varios agentes de union elegidos del grupo que comprende notablemente los polimeros celulosicos, en particular etilcelulosa, hidroxipropilcelulosa e hidroxipropilmetilcelulosa, polimeros acrilicos, povidonas, polivinilalcoholes y sus mezclas, eventualmente un agente diluyente elegido del grupo que comprende notablemente derivados celulosicos, almidones, lactosa, polioles, en particular manitol, y un agente antiestatico elegido del grupo que comprende notablemente silice coloidal, silice precipitada y talco micronizado o no; la invencion se refiere igualmente al metodo de preparacion de estos granulos y las tabletas orodispersables en las cuales se emplean.
MXPA03009908A 2001-05-09 2002-05-03 Granulos cubiertos a base de inhibidor de la enzima de conversion de la angiotensina. MXPA03009908A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0106120A FR2824477B1 (fr) 2001-05-09 2001-05-09 Granules enrobes a base d'inhibiteur de l'enzyme de conversion de l'anfiotensine, leur procede de preparation et comprimes orodispersibles contenant les granules enrobes
PCT/FR2002/001535 WO2002089775A1 (fr) 2001-05-09 2002-05-03 Granules enrobes a base d'inhibiteur de l'enzyme de conversion de l'angiotensine

Publications (1)

Publication Number Publication Date
MXPA03009908A true MXPA03009908A (es) 2005-03-07

Family

ID=8863079

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03009908A MXPA03009908A (es) 2001-05-09 2002-05-03 Granulos cubiertos a base de inhibidor de la enzima de conversion de la angiotensina.

Country Status (14)

Country Link
US (1) US20040171669A1 (es)
EP (1) EP1385489B1 (es)
JP (1) JP2004534024A (es)
CN (1) CN1327827C (es)
AT (1) ATE315385T1 (es)
CA (1) CA2446781C (es)
DE (1) DE60208673T2 (es)
DK (1) DK1385489T3 (es)
ES (1) ES2256485T3 (es)
FR (1) FR2824477B1 (es)
HK (1) HK1062642A1 (es)
MX (1) MXPA03009908A (es)
PT (1) PT1385489E (es)
WO (1) WO2002089775A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2857658B1 (fr) * 2003-07-16 2006-09-22 Rhodia Chimie Sa Nouveaux granules de phosphates de calcium de type hydroxyapatite, leur procede de preparation et leurs applications
WO2005067887A2 (en) * 2004-03-24 2005-07-28 Actavis Group Formulations of ramipril
MX2007005373A (es) * 2004-11-05 2007-08-14 King Pharmaceuticals Res & Dev Composiciones estabilizadas de ramipril y metodos para elaborarlas.
CN101115469A (zh) * 2004-12-28 2008-01-30 卫材R&D管理有限公司 速崩片及其制造方法
EP1681049A1 (fr) * 2005-01-12 2006-07-19 Physica Pharma Composition pharmaceutique et forme galénique correspondante à délitement rapide en bouche, et procédé de fabrication de cette composition
GB0518129D0 (en) * 2005-09-06 2005-10-12 Arrow Int Ltd Ramipril formulation
GB2431579A (en) * 2005-10-28 2007-05-02 Arrow Int Ltd Ramipril formulations
US20070098782A1 (en) * 2005-10-28 2007-05-03 Selamine Limited Ramipril Formulation
US8048449B2 (en) * 2005-12-27 2011-11-01 Jubilant Organosys Ltd. Mouth dissolving pharmaceutical composition and process for preparing the same
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
KR20080076382A (ko) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
PL382311A1 (pl) * 2007-04-27 2008-11-10 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Kompozycja farmaceutyczna o polepszonej stabilności zawierająca inhibitor acetylocholinoesterazy lub farmaceutycznie dopuszczalną jego sól oraz sposób jej wytwarzania
EP2155159B1 (en) * 2007-05-08 2019-07-10 Hercules LLC Robust rapid disintegration tablet formulation
US20100062062A1 (en) * 2008-09-11 2010-03-11 Aethos Pharmaceuticals, Inc. Stabilized Coating for Pharmaceutical Formulations
US9861577B2 (en) 2010-08-31 2018-01-09 Kyowa Hakko Kirin Co., Ltd. Orally disintegrating tablet
KR101896441B1 (ko) 2011-12-21 2018-09-11 메이지 세이카 파루마 가부시키가이샤 국소투여형의 연하장애 개선용 의약품
CN107441495A (zh) * 2012-02-17 2017-12-08 埃吉斯药物私人有限公司 稳定性提高的药物制剂
WO2013135853A1 (en) * 2012-03-15 2013-09-19 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical packaging product for the veterinary medical sector
CN102697749B (zh) * 2012-07-11 2018-01-16 上海上药新亚药业有限公司 盐酸贝那普利片的制备方法
US8568747B1 (en) * 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
US9974768B2 (en) 2013-06-13 2018-05-22 Meiji Seika Pharma Co., Ltd. Pharmaceutical for improving dysphagia
US9463183B1 (en) 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations
CN110623932A (zh) * 2019-10-29 2019-12-31 仁和堂药业有限公司 一种卡托普利片及其应用
CN110917181B (zh) * 2019-11-16 2021-01-26 浙江大学 一种甘草查尔酮b的分离方法及应用
CA3194665A1 (en) 2020-10-05 2022-04-14 Jia-Ning Xiang Modified release compositions of a gamma-hydroxybutyric acid derivative
CN117098533A (zh) 2021-03-19 2023-11-21 凯瑞康宁公司 γ-羟基丁酸衍生物的组合释放型制剂的药物动力学
CN115068434B (zh) * 2022-08-03 2023-05-09 昆山龙灯瑞迪制药有限公司 一种雷米普利片的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1323833C (en) * 1987-04-28 1993-11-02 Yatindra M. Joshi Pharmaceutical compositions in the form of beadlets and method
US4808413A (en) * 1987-04-28 1989-02-28 E. R. Squibb & Sons, Inc. Pharmaceutical compositions in the form of beadlets and method
DE3739690A1 (de) * 1987-11-24 1989-06-08 Hoechst Ag Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
GB9324931D0 (en) * 1993-12-04 1994-01-26 Pfizer Ltd Glutaramide derivatives
CA2159419C (en) * 1994-10-17 2006-07-04 Pieter De Haan Solid pharmaceutical composition comprising an excipient capable of binding water
US5683720A (en) * 1994-10-28 1997-11-04 Fuisz Technologies Ltd. Liquiflash particles and method of making same
FR2766089B1 (fr) * 1997-07-21 2000-06-02 Prographarm Lab Comprime multiparticulaire perfectionne a delitement rapide
US6086920A (en) * 1998-08-12 2000-07-11 Fuisz Technologies Ltd. Disintegratable microspheres
FR2785538B1 (fr) * 1998-11-06 2004-04-09 Prographarm Laboratoires Comprime a delitement rapide perfectionne
FR2785539B1 (fr) * 1998-11-06 2004-04-09 Prographarm Laboratoires Particules enrobees d'ibuprofene cristallin granule
FR2790387B1 (fr) * 1999-03-01 2001-05-18 Prographarm Laboratoires Comprime orodispersible presentant une faible friabilite et son procede de preparation
GB9904629D0 (en) * 1999-03-02 1999-04-21 Danbiosyst Uk Oral drug delivery system
WO2001019348A1 (en) * 1999-09-17 2001-03-22 Mylan Pharmaceuticals Inc. Stabilization of enalapril maleate with maleic acid
US6340471B1 (en) * 1999-12-30 2002-01-22 Alvin Kershman Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals
US6541025B1 (en) * 1999-12-30 2003-04-01 Shear/Kershman Laboratories, Inc. Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals

Also Published As

Publication number Publication date
DE60208673D1 (de) 2006-04-06
JP2004534024A (ja) 2004-11-11
PT1385489E (pt) 2006-05-31
FR2824477A1 (fr) 2002-11-15
US20040171669A1 (en) 2004-09-02
CN1327827C (zh) 2007-07-25
FR2824477B1 (fr) 2005-09-09
CA2446781A1 (fr) 2002-11-14
DE60208673T2 (de) 2006-09-07
ES2256485T3 (es) 2006-07-16
DK1385489T3 (da) 2006-05-22
CA2446781C (fr) 2012-10-16
EP1385489A1 (fr) 2004-02-04
CN1507347A (zh) 2004-06-23
WO2002089775A1 (fr) 2002-11-14
ATE315385T1 (de) 2006-02-15
HK1062642A1 (en) 2004-11-19
EP1385489B1 (fr) 2006-01-11

Similar Documents

Publication Publication Date Title
HK1062642A1 (en) Coated granules based on angiotensin-converting enzyme inhibitor
EP0987263A3 (en) Arylidene and heteroarylidene oxindole derivatives as tyrosine kinase inhibitors
NO20045434L (no) En kombinasjon av en NMDA-antagonist og acetylkolinesteraseinhibitorer for behandlingen av Alzheimers sykdom
AU2001263399A1 (en) 1-(pyrrlolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indo linone derivatives
MXPA02009706A (es) Metodo para sintesis de perindopril y sus sales farmaceuticamente aceptables.
WO2000059902A3 (en) Aryl sulfonyls as factor xa inhibitors
NO20040211L (no) Kombinasjon av en aldosteronreseptor for antagonist og en HMB COA-reduktaseinhibitor
CA2198535A1 (en) Method of increasing testosterone
MX9505065A (es) Composicion farmaceutica, aplicable oralmente.
MX9505064A (es) Composicion farmaceutica, aplicable oralmente.
DK0883405T3 (da) Aminoproteaseinhibitorer
CA2369947A1 (en) Hydroxamic acid derivative
NO20001514L (no) Vitronectin-reseptor-antagonist
GEP20094818B (en) 2-methyl-thieno-benzodiaze-pine formulation
MXPA98002443A (es) Inhibidores de guanidino proteasas.
WO2001056555A3 (en) Use of cox-2 inhibitors for the treatment of constipation
CA2379666A1 (en) Agent for preventing recurrence of cerebrovascular disorder and agent for ameliorating troubles following cerebrovascular disorder and inhibiting progress thereof
CA2310714A1 (en) Process for preparing neuraminidase inhibitor ro-64-0796
DE69625505T2 (de) Guanidino proteiase inhibitoren
CA2338901A1 (en) Prevention of migraine recurrence
CA2317604A1 (en) Matrix metalloprotease inhibitors
AR038305A1 (es) Composicion farmaceutica dispersable oralmente de perindopril
AR038206A1 (es) Composicion farmaceutica dispersable oralmente de ivabradina
WO2003096874A3 (en) Coated sustained release tablets of a hygroscopic compound for once-a-day therapy
WO2001017959A3 (en) Vitronectin receptor antagonists

Legal Events

Date Code Title Description
FG Grant or registration